Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody

Cancer Biotherapy and Radiopharmaceuticals

Volumn 20, Issue 6, 2005, Pages 662-670

  Shen, Sui ^a   DeNardo, Gerald L ^b   Yuan, Aina ^b   Hartmann Siantar, Christine ^c   O'Donnell, Robert T ^b,d   DeNardo, Sally J ^b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^d VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

Cancer therapy; Lymphoma; Radiation dosimetry; Radioimmunotherapy; Splenomegaly

Indexed keywords

COPPER 67; IBRITUMOMAB TIUXETAN; INDIUM 111; IODINE 131; MONOCLONAL ANTIBODY 2IT BAD M170; MONOCLONAL ANTIBODY 2IT BAT LYM 1; MONOCLONAL ANTIBODY BRE3; MONOCLONAL ANTIBODY CHL6 I 131; MONOCLONAL ANTIBODY I 131; MONOCLONAL ANTIBODY L6 I 131; MONOCLONAL ANTIBODY LYM 1; UNCLASSIFIED DRUG; YTTRIUM 90;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; ISOTOPE LABELING; LYMPH NODE METASTASIS; LYMPHOCYTE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; REMISSION; SPLEEN SIZE; SPLENOMEGALY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; FEMALE; HUMANS; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; LYMPH NODES; LYMPHOMA, NON-HODGKIN; RADIOIMMUNOTHERAPY; RETROSPECTIVE STUDIES; SPLEEN; SPLENOMEGALY; TREATMENT OUTCOME;

EID: 30744433871     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2005.20.662     Document Type: Article

References (32)

1. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkins' lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
2. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219.
3. Shen S, DeNardo GL, O'Donnell RT, et al. Impact of splenomegaly on therapeutic response and I-131-LYM-1 dosimetry in patients with B-lymphocytic malignancies. Cancer 1997;80:2553.
4. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3793.
5. 131I-Lym-1 antibody. Cancer Biother Radiopharm 1998;13:239.
6. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 1998;16:3246.
7. 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: A pilot study. Anticancer Res 1998;18:2779.
8. 67Cu-2IT-BAT-Lym-1 for non-Hodgkin' s lymphoma. J Nucl Med 1999;40:2014.
9. DeNardo SJ, O'Grady LF, Richman CM, et al. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Res 1997;17:1745.
10. DeNardo SJ, Kramer EL, O'Donnell RT, et al. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: Results of a phase I clinical trial. J Nucl Med 1997;38:1180.
11. 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A. Clin Cancer Res 1999;5:3243s.
12. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity, and tumor regression in patients with lymphoma. J Nucl Med 1999;40:302.
13. Breiman RS, Beck JW, Korobkin M, et al. Volume determinations using computed tomography. AJR Am J Roentgenol 1982;138:329.
14. Silverman S, DeNardo GL, Siegel E. Determination of spleen size by scintigraphy. Cancer Biother Radiopharm 1999;14:407.
15. DeNardo GL, DeNardo SJ, Macey DJ, et al. Quantitative pharmacokinetics of radiolabeled monoclonal antibodies for imaging and therapy in patients. In: Srivastava SC, ed. Radiolabeled Monocolonal Antibodies for Imaging and Therapy. New York: Plenum, 1988:293.
16. 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Nucl Med 1999;40:1317.
17. Shen S, DeNardo GL, Sgouros G, et al. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med 1999;40:2102.
18. Snyder WS, Ford MR, Warner GG, et al. 'S', Absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD Pamphlet No. 11. New York, Society of Nuclear Medicine, 1975.
19. Stabin MG. MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996;37:538.
20. Coffey JL, Watson EE. Calculating dose from remaining body activity: A comparison of two methods. Med Phys 1979;6:307.
21. Shen S, DeNardo GL, Macey DJ, et al. Practical determination of organ S values for individual patients for therapy. Nucl Med Biol 1997;24:447.
22. Brownell GL, Ellett WH, Reddy AR. Absorbed fractions for photon dosimetry. MIRD Pamphlet No. 3. Society of Nuclear Medicine, New York 1968.
23. Ellett WH, Humes RM. Absorbed fractions for small volumes containing photon-emitting radioactivity. J Nucl Med 1971;(Suppl 5):25.
24. Spencer RP, Knowlton AH. Radiocolloid scans in evaluating splenic response to external radiation. J Nucl Med 1975;16:123.
25. Stevens M, Brown E, Zipursky A. The effect of abdominal radiation on spleen function: A study in children with Wilms' tumor. Pediatr Hematol Oncol 1986;3:69.
26. Snyder WS, Cook MJ, Nasset ES, et al. Report of the Task Group on Reference Man. International Commission on Radiological Protection No. 23. Oxford, UK: Pergamon Press, 1975.
27. Xiros N, Economopoulos T, Christodoulidis C, et al. Splenectomy in patients with malignant non-Hodgkin's lymphoma. Eur J Haematol 2000;64:145.
28. National Cancer Institute. Treatment Options by Stage. www.cancer.gov/cancertopics/pdg/treatment/CLL/Patient and www.cancer.gov/ cancertopics/pdg/treatment/CLL/Patient Accessed May 14, 2005.
29. Humm JL, Macklis RM, Bump K, et al. Internal dosimetry using data derived from autoradiographs. J Nucl Med 1993;34:1811.
30. Sgouros G, Chiu S, Pentlow KS, et al. Three-dimensional dosimetry for radioimmunotherapy treatment planning. J Nucl Med 1993;34:1595.
31. Furhang EE, Chui CS, Kolbert KS, et al. Implementation of a Monte Carlo dosimetry method for patient-specific internal emitter therapy. Med Phys 1997;24:1163.
32. Giap HB, Macey DJ, Podoloff DA. Development of a SPECT-based three-dimensional treatment planning system for radioimmunotherapy. J Nucl Med 1995;36:1885.